Related content

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

By Terret C.   Zanetta S.   Roche H.   Schellens J.H.M.   Faber M.N.   Wanders J.   Ravic M.   Droz J.P.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1097-1104

Elsevier

Access to resources Recommend Favorite

A Phase I Trial of 5-day Chronomodulated Infusion of 5-Fluorouracil and 1-Folinic Acid in Patients with Metastatic Colorectal Cancer

By Garufi C.   Levi F.   Aschelter A.M.   Pace R.   Giunta S.   Nistico C.   Galla D.A.P.   Silecchia G.F.   Franchi F.   Narduzzi C.   Terzoli E.  

European Journal of Cancer, Vol. 33, Iss. 10, 1997-09 ,pp. : 1566-1571

Elsevier

Access to resources Recommend Favorite

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes

By Awada A.   Biganzoli L.   Cufer T.   Beex L.   Lohrisch C.   Batter V.   Hamilton A.   Nooij M.   Piccart M.  

European Journal of Cancer, Vol. 38, Iss. 6, 2002-01 ,pp. : 773-778

Elsevier

Access to resources Recommend Favorite

A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule

By Fyfe D.   Price C.   Langley R.E.   Pagonis C.   Houghton J.   Osborne L.   Woll P.J.   Gardner C.   Baguley B.C.   Carmichael J.  

Cancer Chemotherapy and Pharmacology, Vol. 47, Iss. 4, 2001-04 ,pp. : 333-337

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I Trial of Gemcitabine Administered as a 96-h Continuous Intravenous Infusion in Patients with Advanced Carcinoma and Lymphoma

By  

Medical Oncology, Vol. 23, Iss. 3, 2006-09 ,pp. : 369-376

Humana Press, Inc

Access to resources Recommend Favorite